The authors analyze the diagnostic and classification criteria in systemic sclerosis (SSc), the clinical variants diffuse and limited, and the recent concepts of SSc sine scleroderma and early SSc. It is also discussed the limitations in the validation of the methods to measure SSc activity and damage, and the recent efforts in order to standardize them.4414045Curzio, C., Discussioni Anatomico-Pratiche Di Un Raro, E Stravagante Morbo Cutaneo in Una Giovanne Donna Felicemente Curato In Questo Grande Ospedale Degl'Incurabili, p. 1753. , Napoli, Giovanne di SimoneBetschler, J.W., Induratio telae cellulosae (Scleroderma) (1832) Ann Klin Anstalt Univ Breslau, 1, pp. 209-210Rodnan, G.P., Benedek, T.G., An historical account of the study of progressive systemic sclerosis (diffuse scleroderma) (1962) Ann Rheum Dis, 57, pp. 305-319Matsui, S., Uber die Pathologie und pathogenese von Sklerodermia universalis (1924) Mitt Med Fakult Kaiserl Univ Tokyo, 31, pp. 55-116Klemperer, P., Pollack, A.D., Baher, G., Diffuse collagen disease: Acute disseminated lupus erythematosus and diffuse scleroderma (1942) JAMA, 119, pp. 331-355Goetz, R.H., Pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera (1945) Clin Proc, 4, pp. 337-392Leroy, E.C., Black, C., Fleischmajer, R., Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis (1988) J Rheumatol, 15, pp. 202-205Masi, A.T., Classification of systemic sclerosis (scleroderma): Relationship of cutaneous subgroups in early disease to outcome and serologic reactivity (1988) J Rheumatol, 15, pp. 894-898O'Leary, P.A., Nomland, R., A clinical study of one hundred and three cases of scleroderma (1930) Am J Med Sci, 180, pp. 95-112Winterbauer, R.H., Multiple telangiestasia, Raynaud ́s phenomenon, sclerodactily and subcutaneous calcinosis: A syndrome mimicking hereditary hemorrhagic telangiectasia (1964) Johns Hopkins Hosp Bull, 114, pp. 361-383Carr, R., Heisel, E.B., Stevenson, T.D., CRST syndrome: A benign variant of scleroderma (1965) Arch Dermatol, 92, pp. 519-525Fritzler, M.J., Kinsella, T.D., Garbutt, E., The CREST syndrome: A distinct serologic entity with anticentromere antibodies (1980) Am J Med, 69, pp. 520-526Masi, A.T., Rodnan, G.P., Medsger Jr., T.A., Prelimianty criteria for the classification of systemic sclerosis (scleroderma) (1980) Arthritis Rheum, 23, pp. 581-590der Arbeitsgruppe, A.D.F., Klinik der progressiven systemichen sklerodermie (PSS): Multizentrische untersuchungen an 194 patienten (1986) Der Hautartz, 37, pp. 320-324Giordano, M., Valentini, G., Migliaresi, S., Piccillo, N., Vatti, M., Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis (1986) J Rheumatol, 13, pp. 911-916Barnett, A.J., Miller, M.H., Littlejohn, G.O., A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): The value of a simple cutaneous classification in the early stages of the disease (1988) J Rheumatol, 15, pp. 276-283Poormoghim, H., Lucas, M., Fertig, N., Medsger Jr., T.A., Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients (2000) Arthritis Rheum, 43, pp. 444-451Leroy, E.C., Medsger Jr., T.A., Criteria for the classification of early systemic sclerosis (2001) J Rheumatol, 28, pp. 1573-1576Medsger Jr., T.A., Bombardieri, S., Czirjak, L., Scorza, R., della Rossa, A., Bencivelli, W., Assessment of disease severity and prognosis (2003) Clin Exp Rheumatol, 21 (SUPPL. 29), pp. S42-S46Fries, J.F., Hochberg, M.C., Medsger Jr., T.A., Criteria for rheumatic diseases: Different types and different functions (1994) Arthritis Rheum, 37, pp. 454-462Medsger Jr., T.A., Silman, A.J., Steen, V.D., A disease severity scale for systemic sclerosis: Development and testing (1999) J Rheumatol, 26, pp. 2159-2167Valentini, G., Silman, A.J., Veale, D., Assessment of disease activity (2003) Clin Exp Rheumatol, 21 (SUPPL. 29), pp. S39-S41Clements, P.J., Peter, J.B., Agopian, M.S., Elevated serum levels of soluble interleukin-2 receptor, interleukin-2 and neopterin in diffuse and limited scleroderma: Effects of chlorambucil (1990) J Rheumatol, 17, pp. 908-910Stevens, W., Vancheeswaran, R., Black, C.M., Alpha-interferon-2a (Roferon-A) in the treatment of diffuse cutaneous scleroderma: A pilot study (1992) Br J Rheumatol, 31, pp. 683-689Veale, D.J., Fearon, U.M., Henshaw, W.K., Clinical and laboratory measures of disease activity in systemic sclerosis (2001) Arthritis Rheum, 44 (SUPPL.), pp. S327Valentini, G., della Rossa, A., Bombardieri, S., European multicentre study to define disease activity criteria for systemic sclerosis II. Identification of disease activity variables and development of preliminary activity indexes (2001) Ann Rheum Dis, 60, pp. 592-598Valentini, G., Bencivelli, W., Bombardieri, S., European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria (2003) Ann Rheum Dis, 62, pp. 901-903The assessment of the patient with systemic sclerosis (2003) Clin Exp Rheumatol, 21 (SUPPL. 29), pp. S01-S56. , Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S (Editores)Fertig, N., Lucas, M., Feghali, C.A., Wright, T.M., Medsger Jr., T.A., Selected cytokines and soluble protein mediators as correlates of disease activity in systemic sclerosis with diffuse cutaneous involvement (2001) Arthritis Rheum, 44 (SUPPL.), pp. S327Hu, P.Q., Fertig, N., Medsger Jr., T.A., Wright, T.M., Correlation of serum anti-DNA topoisomerase I antibody levels with disease activity in systemic sclerosis (2003) Arthritis Rheum, 48, pp. 1363-1373Merkel, P.A., Herlyn, K., Martin, R.W., Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon (2002) Arthritis Rheum, 46, pp. 2410-2420